ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Nutman TB , 2017. Human infection with Strongyloides stercoralis and other related Strongyloides species. Parasitology 144: 263–273.
-
2.
Vargas Barahona L et al., 2023. Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: A global research network with a follow-up multicenter case–control study. Ther Adv Infect Dis 10: 20499361231159481.
-
3.
Henao-Martínez AF , Orkin CM , Titanji BK , Rodriguez-Morales AJ , Salinas JL , Franco-Paredes C , Tuells J , Chastain DB , 2023. Hospitalization risk among patients with mpox infection – A propensity score matched analysis. Ther Adv Infect Dis 10: 20499361231196683.
-
4.
Geri G , Rabbat A , Mayaux J , Zafrani L , Chalumeau-Lemoine L , Guidet B , Azoulay E , Pène F , 2015. Strongyloides stercoralis hyperinfection syndrome: A case series and a review of the literature. Infection 43: 691–698.
-
5.
Ye L , Taylor GP , Rosadas C , 2022. Human T-cell lymphotropic virus type 1 and Strongyloides stercoralis co-infection: A systematic review and meta-analysis. Front Med (Lausanne) 9: 832430.
-
6.
Marcos LA , Terashima A , Canales M , Gotuzzo E , 2011. Update on strongyloidiasis in the immunocompromised host. Curr Infect Dis Rep 13: 35–46.
-
7.
Igra-Siegman Y , Kapila R , Sen P , Kaminski ZC , Louria DB , 1981. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 3: 397–407.
-
8.
Inagaki K , Bradbury RS , Hobbs CV , 2022. Hospitalizations associated with strongyloidiasis in the United States, 2003–2018. Clin Infect Dis 75: 1548–1555.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 3915 | 3580 | 135 |
| Full Text Views | 163 | 154 | 8 |
| PDF Downloads | 183 | 169 | 4 |
Clinical Characteristics and Outcomes of Disseminated Strongyloidiasis in the United States—A Multicenter Network Analysis
Andrés F. Henao-Martínez
Andrés F. Henao-Martínez
Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, Colorado;
Search for other papers by Andrés F. Henao-Martínez in
Current site
Google Scholar
PubMed
Search for other papers by Andrés F. Henao-Martínez in
Current site
Google Scholar
PubMed
Christian Olivo Freites
Christian Olivo Freites
Ryan Health, Infectious Diseases, New York, New York;
Search for other papers by Christian Olivo Freites in
Current site
Google Scholar
PubMed
Search for other papers by Christian Olivo Freites in
Current site
Google Scholar
PubMed
Nelson I. Agudelo Higuita
Nelson I. Agudelo Higuita
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma;
Instituto de Enfermedades Infecciosas y de Parasitología Antonio Vidal, Tegucigalpa, Honduras;
Search for other papers by Nelson I. Agudelo Higuita in
Current site
Google Scholar
PubMed
Instituto de Enfermedades Infecciosas y de Parasitología Antonio Vidal, Tegucigalpa, Honduras;
Search for other papers by Nelson I. Agudelo Higuita in
Current site
Google Scholar
PubMed
Luis A. Marcos
Luis A. Marcos
Division of Infectious Diseases, Departments of Medicine, Microbiology and Immunology, Stony Brook University, Stony Brook, New York;
Search for other papers by Luis A. Marcos in
Current site
Google Scholar
PubMed
Search for other papers by Luis A. Marcos in
Current site
Google Scholar
PubMed
Daniel B. Chastain
Daniel B. Chastain
Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, Georgia;
Search for other papers by Daniel B. Chastain in
Current site
Google Scholar
PubMed
Search for other papers by Daniel B. Chastain in
Current site
Google Scholar
PubMed
Amir M. Mohareb
Amir M. Mohareb
Center for Global Health, Massachusetts General Hospital, Boston, Massachusetts;
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts;
Department of Medicine, Harvard Medical School, Boston, Massachusetts;
Search for other papers by Amir M. Mohareb in
Current site
Google Scholar
PubMed
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts;
Department of Medicine, Harvard Medical School, Boston, Massachusetts;
Search for other papers by Amir M. Mohareb in
Current site
Google Scholar
PubMed
Jose Tuells
Jose Tuells
Department of Community Nursing, Preventive Medicine and Public Health and History of Science, University of Alicante, Alicante, Spain;
Search for other papers by Jose Tuells in
Current site
Google Scholar
PubMed
Search for other papers by Jose Tuells in
Current site
Google Scholar
PubMed
Salvador Villalpando-Carrion
Salvador Villalpando-Carrion
Hospital Infantil de México, Ciudad de México, México;
Search for other papers by Salvador Villalpando-Carrion in
Current site
Google Scholar
PubMed
Search for other papers by Salvador Villalpando-Carrion in
Current site
Google Scholar
PubMed
Carlos Franco-Paredes
Carlos Franco-Paredes
Hospital Infantil de México, Ciudad de México, México;
Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Republic of Panama;
Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado
Search for other papers by Carlos Franco-Paredes in
Current site
Google Scholar
PubMed
Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Republic of Panama;
Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado
Search for other papers by Carlos Franco-Paredes in
Current site
Google Scholar
PubMed
ABSTRACT.
Human strongyloidiasis is a potentially life-threatening parasitic disease among immunocompromised hosts. We aim to determine the factors and mortality associated with disseminated strongyloidiasis. We conducted a U.S.-based multicenter retrospective cohort study to determine 90-day clinical outcomes for people diagnosed with Strongyloides infection in the TriNetX patient database. We identified adult patients with the International Classification of Diseases (10th revision, clinical modification) code for Strongyloides infection (B78) or a positive Strongyloides IgG antibody test and captured outcomes at 90 days. We identified 5,434 patients with strongyloidiasis, of whom 48 had disseminated strongyloidiasis for 0.9% prevalence of disseminated disease. Systemic connective tissue disorders, pulmonary eosinophilia, liver cirrhosis, blood disorders (monoclonal gammopathy, aplastic anemia, and lymphoid malignancy), malnutrition, alcohol use disorder, and transplantation status were frequent in patients with disseminated disease. Mortality was significantly higher in people with disseminated disease at 30 days (21%). The 90-day risk of hospitalization, bacteremia, and acute respiratory distress syndrome (ARDS) was higher in those with disseminated infection. People with disseminated strongyloidiasis had a heightened risk of hospitalization, bacteremia, acute respiratory distress syndrome, and mortality. The population at risk for severe strongyloidiasis infection is evolving, reflecting conditions in which glucocorticoids or additional immunosuppressive medications are commonly used for treatment.
- Supplemental Materials (PDF 176.29 KB)
Author Notes
Data availability: The corresponding author had full access to data in the study and was ultimately responsible for submitting the manuscript for publication. The aggregated datasets generated and analyzed in the current study are available from the TriNetX platform. Any data displayed on the TriNetX platform in aggregate form, or any patient-level data provided in a data set generated by the TriNetX platform, only contains de-identified data as per the de-identification standard defined in Section 164.514(a) of the HIPAA Privacy Rule.
Authors’ addresses: Andrés F. Henao-Martínez, Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, CO, E-mail: andres.henaomartinez@cuanschutz.edu. Christian Olivo Freites, Ryan Health, Infectious Diseases, New York, NY, E-mail: christianolivo.freites@ryanhealth.org. Nelson I. Agudelo Higuita, University of Oklahoma Health Sciences Center, Oklahoma City, OK, and Instituto de Enfermedades Infecciosas y de Parasitología Antonio Vidal, Tegucigalpa, Honduras, E-mail: nelson-agudelo-higuita@ouhsc.edu. Luis A. Marcos, Division of Infectious Diseases, Departments of Medicine, Microbiology and Immunology, Stony Brook University, Stony Brook, NY, E-mail: luis.marcosraymundo@stonybrookmedicine.edu. Daniel B. Chastain, Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, E-mail: daniel.chastain@uga.edu. Amir M. Mohareb, Center for Global Health, Massachusetts General Hospital, Boston, MA, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, and Department of Medicine, Harvard Medical School. Boston, MA, E-mail: amohareb@mgh.harvard.edu. Jose Tuells, Department of Community Nursing, Preventive Medicine and Public Health and History of Science, University of Alicante, Alicante, Spain, E-mail: tuells@ua.es. Salvador Villalpando-Carrion, Hospital Infantil de México, Ciudad de México, México, E-mail: villalpandoca@himfg.edu.mx. Carlos Franco-Paredes, Hospital Infantil de México, Ciudad de México, México, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Republic of Panama, and Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO., E-mail: carlos.franco.paredes@gmail.com.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Nutman TB , 2017. Human infection with Strongyloides stercoralis and other related Strongyloides species. Parasitology 144: 263–273.
-
2.
Vargas Barahona L et al., 2023. Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: A global research network with a follow-up multicenter case–control study. Ther Adv Infect Dis 10: 20499361231159481.
-
3.
Henao-Martínez AF , Orkin CM , Titanji BK , Rodriguez-Morales AJ , Salinas JL , Franco-Paredes C , Tuells J , Chastain DB , 2023. Hospitalization risk among patients with mpox infection – A propensity score matched analysis. Ther Adv Infect Dis 10: 20499361231196683.
-
4.
Geri G , Rabbat A , Mayaux J , Zafrani L , Chalumeau-Lemoine L , Guidet B , Azoulay E , Pène F , 2015. Strongyloides stercoralis hyperinfection syndrome: A case series and a review of the literature. Infection 43: 691–698.
-
5.
Ye L , Taylor GP , Rosadas C , 2022. Human T-cell lymphotropic virus type 1 and Strongyloides stercoralis co-infection: A systematic review and meta-analysis. Front Med (Lausanne) 9: 832430.
-
6.
Marcos LA , Terashima A , Canales M , Gotuzzo E , 2011. Update on strongyloidiasis in the immunocompromised host. Curr Infect Dis Rep 13: 35–46.
-
7.
Igra-Siegman Y , Kapila R , Sen P , Kaminski ZC , Louria DB , 1981. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 3: 397–407.
-
8.
Inagaki K , Bradbury RS , Hobbs CV , 2022. Hospitalizations associated with strongyloidiasis in the United States, 2003–2018. Clin Infect Dis 75: 1548–1555.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 3915 | 3580 | 135 |
| Full Text Views | 163 | 154 | 8 |
| PDF Downloads | 183 | 169 | 4 |